Park Square Financial Group, LLC Pharma Cyte Biotech, Inc. Transaction History
Park Square Financial Group, LLC
- $145 Billion
- Q4 2024
A detailed history of Park Square Financial Group, LLC transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Park Square Financial Group, LLC holds 37 shares of PMCB stock, worth $63. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37Holding current value
$63% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PMCB
# of Institutions
28Shares Held
706KCall Options Held
9.3KPut Options Held
4.6K-
Vanguard Group Inc Valley Forge, PA192KShares$330,9050.0% of portfolio
-
Geode Capital Management, LLC Boston, MA165KShares$283,3450.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$158,3897.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$142,2900.07% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.3KShares$84,7960.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $35.7M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...